Pranlukast

Pranlukast

Systematic (IUPAC) name
N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-7-yl]-4-(4-phenylbutoxy)benzamide
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Routes	Oral
Pharmacokinetic data
Metabolism	Hepatic (mainly CYP3A4)[1]
Half-life	1.5 hours[1]
Identifiers
CAS number	103177-37-3 Y
ATC code	R03DC02
PubChem	CID 4887
DrugBank	DB01411
ChemSpider	4718 Y
UNII	TB8Z891092 Y
ChEMBL	CHEMBL21333 Y
Chemical data
Formula	C27H23N5O4
Mol. mass	481.503 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) Y Key:NBQKINXMPLXUET-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.

References

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. v t e